This is done through a variety of complex mechanisms and interactions between GLP1 and various parts of the body, she explains, such as: GLP-1 is produced by the taste buds themselves GLP-1 is produced in the gut, which may be influenced by taste, especially the perception of sweet taste GLP-1 is produced in the brain, which is also influenced by taste Studies have shown that people on GLP-1 drugs report changes in their cravings for certain foods, including sweets and rich or fatty foods, which could certainly be related to a (negative) change in the way they perceive these foods on the taste buds, says Avantika Waring, M.D., endocrinologist and chief medical officer at 9amHealth
GLP-1 can make people lose weight, and so, if obesity increases the risk of cancer, then, hypothetically speaking, losing weight through GLP-1 may actually reduce the risk of developing cancer, said Chiang, now a medical oncology fellow at the Northwell Health Cancer Institute in New York
The Obesity Medicine Association released a position statement earlier this year stating that they do not support use of compounded semaglutide or tirzepatide and warning consumers against their use
Similarly, Dings research team engineered a system linking two shRNA transcription plasmids targeting MDR-related genes (P-glycoprotein and survivin) to doxorubicin (DOX)-loaded DNA origami via disulfide bonds [57]
